10x Genomics, Inc. TXG Gain on litigation settlement
Gain on litigation settlement at other companies
Other financials
Where this comes from
Reported directly by 10x Genomics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:LitigationSettlementGain.
The official record: 10x Genomics, Inc.’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Questions, answered.
- What is 10x Genomics, Inc.'s gain on litigation settlement?
- 10x Genomics, Inc. (TXG) reported gain on litigation settlement of $0 in Q1 2026.
- How has 10x Genomics, Inc.'s gain on litigation settlement changed year-over-year?
- 10x Genomics, Inc.'s gain on litigation settlement decreased by 100.0% year-over-year, from $9.2M to $0.
- What does gain on litigation settlement mean?
- This metric represents non-recurring financial inflows resulting from the successful resolution of legal disputes, patent litigation, or intellectual property settlements. It reflects one-time gains that are distinct from core operational activities and should be excluded when evaluating the underlying recurring profitability of the business. Investors monitor this to distinguish between sustainable revenue growth and transient accounting benefits derived from legal outcomes.